2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05176093 (ClinicalTrials.gov)	November 14, 2021	5/11/2021	A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis	A 6-Month Extension Study Following Protocol VMALS-002-2 (A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis)	Amyotrophic Lateral Sclerosis	Biological: Engensis;Other: Placebo	Helixmith Co., Ltd.	NULL	Completed	18 Years	80 Years	All	8	Phase 2	United States;Korea, Republic of
2	NCT04632225 (ClinicalTrials.gov)	February 9, 2021	29/10/2020	Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis	A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Biological: Engensis;Other: Placebo	Helixmith Co., Ltd.	NULL	Completed	18 Years	80 Years	All	18	Phase 2	United States;Korea, Republic of